Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32990
Full metadata record
DC FieldValueLanguage
dc.contributor.authorScheldeman, Lauranne-
dc.contributor.authorWouters, Anke-
dc.contributor.authorBertels, Jeroen-
dc.contributor.authorDupont, Patrick-
dc.contributor.authorCheng, Bastian-
dc.contributor.authorEbinger, Martin-
dc.contributor.authorEndres, Matthias-
dc.contributor.authorFiebach, Jochen B-
dc.contributor.authorGerloff, Christian-
dc.contributor.authorMuir, Keith W-
dc.contributor.authorNighoghossian, Norbert-
dc.contributor.authorPedraza, Salvador-
dc.contributor.authorSimonsen, Claus Z-
dc.contributor.authorThijs, Vincent N-
dc.contributor.authorThomalla, Götz-
dc.contributor.authorLemmens, Robin-
dc.date2023-
dc.date.accessioned2023-06-07T02:37:23Z-
dc.date.available2023-06-07T02:37:23Z-
dc.date.issued2023-06-
dc.identifier.citationStroke 2023en_US
dc.identifier.issn1524-4628-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32990-
dc.description.abstractReversibility of the diffusion-weighted imaging (DWI) lesion means that not all of the DWI lesion represents permanently injured tissue. We investigated DWI reversibility and the association with thrombolysis, reperfusion and functional outcome in patients from the WAKE-UP trial (Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-Up Stroke). In this retrospective analysis of WAKE-UP, a randomized controlled trial (RCT) between September 2012 and June 2017 in Belgium, Denmark, France, Germany, Spain and United Kingdom, a convolutional neural network segmented the DWI lesions (b=1000 s/mm2) at baseline and follow-up (24 hours). We calculated absolute and relative DWI reversibility in 2 ways: first, a volumetric (baseline volume-24-hour volume >0) and second, a voxel-based (part of baseline lesion not overlapping with 24-hour lesion) approach. We additionally defined relative voxel-based DWI-reversibility >50% to account for coregistration inaccuracies. We calculated the odds ratio for reversibility according to treatment arm. We analyzed the association of reversibility with excellent functional outcome (modified Rankin Scale score of 0-1), in a multivariable model. In 363 patients, the median DWI volume was 3 (1-10) mL at baseline and 6 (2-20) mL at follow-up. Volumetric DWI reversibility was present in 19% (69/363) with a median absolute reversible volume of 1 mL (0-2) or 28% (14-50) relatively. Voxel-based DWI reversibility was present in 358/363 (99%) with a median absolute volume of 1 mL (0-2), or 22% (9-38) relatively. In 18% of the patients (67/363), relative voxel-based DWI reversibility >50% was present. Volumetric DWI reversibility and relative voxel-based DWI reversibility >50% was more frequent in patients treated with alteplase versus placebo (OR, 1.86 [95% CI, 1.09-3.17] and OR, 2.03 [95% CI, 1.18-3.50], respectively). Relative voxel-based DWI reversibility >50% was associated with excellent functional outcome (OR, 2.30 [95% CI, 1.17-4.51]). Small absolute volumes of DWI reversibility were present in a large proportion of randomized patients in the WAKE-UP trial. Reversibility was more often present after thrombolysis.en_US
dc.language.isoeng-
dc.subjectarmen_US
dc.subjectdiagnosisen_US
dc.subjectischemic strokeen_US
dc.subjectodds ratioen_US
dc.subjectreperfusionen_US
dc.titleReversibility of Diffusion-Weighted Imaging Lesions in Patients With Ischemic Stroke in the WAKE-UP Trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleStrokeen_US
dc.identifier.affiliationDepartment of Neurology, University Hospitals Leuven, Belgiumen_US
dc.identifier.affiliationDepartment of Neurosciences, Experimental Neurology KU Leuven, University of Leuvenen_US
dc.identifier.affiliationProcessing Speech and Images, Department of Electrial Engineering, University of Leuven, Belgiumen_US
dc.identifier.affiliationDepartment of Neurosciences, Laboratory for Cognitive Neurology KU Leuven, University of Leuven, Belgiumen_US
dc.identifier.affiliationKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germanyen_US
dc.identifier.affiliationCenter for Stroke Research Berlin Charit. - Universit.tsmedizin Berlin, Germanyen_US
dc.identifier.affiliationKlinik und Hochschulambulanz für Neurologie, Charit. - Universit.tsmedizin Berlin, Germanyen_US
dc.identifier.affiliationNeurologyen_US
dc.identifier.affiliationSchool of Psychology & Neuroscience, University of Glasgow, United Kingdomen_US
dc.identifier.affiliationDepartment of Stroke Medicine, Universit. Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA- Lyon, Hospices Civils de Lyon, Franceen_US
dc.identifier.affiliationDepartment of Radiology, Institut de Diagnostic per la Image Hospital Dr Josep Trueta, Institut d'Investigaci. Biomedica de Girona Parc Hospitalari Marti i Julia de Salt - Edifici M2, Girona, Spainen_US
dc.identifier.affiliationDepartment of Neurology, Aarhus University Hospital, Denmarken_US
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen_US
dc.identifier.affiliationExcellenceCluster NeuroCureen_US
dc.identifier.affiliationCenter for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgiumen_US
dc.identifier.affiliationGerman Center for Neurodegenerative Diseases, partner site Berlinen_US
dc.identifier.affiliationDepartment of Neurology, Amsterdam University Medical Centers, the Netherlandsen_US
dc.identifier.affiliationLeuven Brain Institute, Belgiumen_US
dc.identifier.affiliationKlinik für Neurologie, Medical Park Berlin Humboldtmühle, Germanyen_US
dc.identifier.affiliationGerman Center for Cardiovascular Research, partner site Berlinen_US
dc.identifier.doi10.1161/STROKEAHA.122.041505en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-5263-3550en_US
dc.identifier.orcid0000-0001-5229-2699en_US
dc.identifier.orcid0000-0001-7206-2671en_US
dc.identifier.orcid0000-0003-1980-2540en_US
dc.identifier.orcid0000-0003-2434-1822en_US
dc.identifier.orcid0000-0002-5073-4665en_US
dc.identifier.orcid0000-0001-6520-3720en_US
dc.identifier.orcid0000-0002-7936-6958en_US
dc.identifier.orcid0000-0002-6484-8882en_US
dc.identifier.orcid0000-0003-0594-4409en_US
dc.identifier.orcid0000-0003-2517-4413en_US
dc.identifier.orcid0000-0003-1363-0266en_US
dc.identifier.orcid0000-0002-6614-8417en_US
dc.identifier.orcid0000-0002-4785-1449en_US
dc.identifier.orcid0000-0002-4948-5956en_US
dc.identifier.pubmedid37158080-
dc.description.volume54-
dc.description.issue6-
dc.description.startpage1560-
dc.description.endpage1568-
dc.subject.meshtermssecondaryStroke/diagnostic imaging-
dc.subject.meshtermssecondaryStroke/drug therapy-
dc.subject.meshtermssecondaryStroke/pathology-
dc.subject.meshtermssecondaryDiffusion Magnetic Resonance Imaging/methods-
dc.subject.meshtermssecondaryTissue Plasminogen Activator/therapeutic use-
dc.subject.meshtermssecondaryIschemic Stroke/drug therapy-
local.name.researcherThijs, Vincent N
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptNeurology-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.